Here are some clinical trials that could send Big Pharma shares soaring, or crashing, in 2025. Eli Lilly. The world’s biggest ...

It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

In a world grappling with obesity and chronic disease, GLP-1 drugs like Ozempic are emerging as transformative game-changers.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...